

CSD/BSE&NSE/BM/2024-25

February 12, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Integrated Filing (Financial) - Unaudited Financial Results of Suven Pharmaceuticals Limited ("the Company") for the quarter and nine months ended December 31, 2024

.....

Pursuant to Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December 2024, we enclose herewith the Integrated Filing (Financial) including the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report of the Statutory Auditors.

This is for your information and record.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
*Company Secretary, Compliance Officer and
Head-Legal*

Encl: as above

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



SUVEN PHARMACEUTICALS LIMITED

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2024

		Rs. in Crores					
PART - I		STANDALONE					
Sl. No.	PARTICULARS	Quarter ended			Nine months ended		For the year ended
		31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Revenue from operations	275.39	236.06	212.82	733.54	781.47	1,024.99
	Other income	15.18	13.43	13.97	46.56	38.23	55.09
	Total income	290.57	249.49	226.79	780.10	819.70	1,080.08
2	Expenses						
	a) Cost of materials consumed	55.11	39.17	60.65	129.01	185.22	248.38
	b) Changes in inventories of finished goods and work-in-progress	(7.97)	6.84	6.39	20.84	36.86	53.88
	c) Employee benefits expense	50.34	44.25	32.57	137.46	89.39	126.88
	d) Finance costs	2.60	1.47	2.15	5.67	5.14	7.43
	e) Depreciation and amortisation expense	13.44	12.29	11.38	37.73	33.13	48.79
	f) Other expenses	62.45	44.79	44.15	146.72	132.24	185.95
	Total expenses	175.97	148.81	157.29	477.43	481.98	671.31
3	Profit before tax (1-2)	114.60	100.68	69.50	302.67	337.72	408.77
4	Tax expenses						
	a) Current tax	35.22	27.91	13.85	83.15	79.45	98.14
	b) Current tax - earlier years	6.57	-	(0.78)	6.57	(0.78)	(0.78)
	c) Deferred tax	(13.54)	(3.56)	4.07	(14.80)	7.66	6.59
5	Net Profit for the period/year (3-4)	86.35	76.33	52.36	227.75	251.39	304.82
6	Other comprehensive income/ (loss)						
6.a	(i) Items that will not be reclassified to profit or loss	(0.11)	(0.10)	(1.13)	(0.21)	(1.12)	(0.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.02	0.03	0.28	0.05	0.28	0.10
6.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive loss	(0.09)	(0.07)	(0.85)	(0.16)	(0.84)	(0.29)
7	Total comprehensive income for the period/year	86.26	76.26	51.51	227.59	250.55	304.53
8	Paid-up equity share capital	25.46	25.46	25.46	25.46	25.46	25.46
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
9	Other equity						2,030.44
10	Earning Per Share (EPS)-Face value of Rs.1/- each)						
	a) Basic	3.39	3.00	2.06	8.95	9.88	11.97
	b) Diluted	3.37	2.98	2.06	8.91	9.88	11.97
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

SIGNED FOR IDENTIFICATION PURPOSES





SUVEN PHARMACEUTICALS LIMITED

Regd. Off: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093

Rs. in Crores

PART - II		CONSOLIDATED					
Sl. No.	PARTICULARS	Quarter ended			Nine months ended		For the year ended
		31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Revenue from operations	307.15	257.72	219.82	795.56	798.42	1,051.35
	Other income	15.71	14.12	14.34	47.99	44.85	61.91
	Total income	322.86	271.84	234.16	843.55	843.27	1,113.26
2	Expenses						
	a) Cost of materials consumed	67.04	47.08	63.52	152.42	194.45	265.88
	b) Changes in inventories of finished goods and work-in-progress	(11.41)	4.98	8.91	18.87	36.86	49.15
	c) Employee benefits expense	63.29	51.87	34.79	160.48	96.14	135.92
	d) Finance costs	3.33	1.67	2.16	6.60	5.15	7.45
	e) Depreciation and amortisation expense	20.35	16.96	12.79	50.71	37.35	54.60
	f) Other expenses	70.53	49.78	46.52	162.15	138.50	194.59
	Total expenses	213.13	172.34	168.69	551.23	508.45	707.59
3	Profit before tax and share of profit/(loss) of Associate (1-2)	109.73	99.50	65.47	292.32	334.82	405.67
4	Add : Share of profit/ (Loss) of Associate	-	-	-	-	-	-
5	Profit before tax (3+4)	109.73	99.50	65.47	292.32	334.82	405.67
6	Tax expenses						
	a) Current tax	35.03	27.91	15.43	82.96	81.03	99.58
	b) Current tax - earlier years	6.57	-	(0.78)	6.57	(0.78)	(0.78)
	c) Deferred tax	(15.16)	(10.39)	4.07	(23.25)	7.66	6.59
7	Net Profit for the period/year (5-6)	83.29	81.98	46.75	226.04	246.91	300.28
8	Net Profit for the period/year attributable to						
	a) Shareholders of the company	82.88	82.21	46.75	225.86	246.91	300.28
	b) Non-controlling interest	0.41	(0.23)	-	0.18	-	-
9	Other comprehensive income						
9.a	(i) Items that will not be reclassified to profit or loss	(0.09)	(0.10)	(1.12)	(0.19)	(1.12)	0.11
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.02	0.03	0.28	0.05	0.28	0.10
9.b	(i) Items that will be reclassified to profit or loss	2.81	0.01	-	3.41	-	13.00
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income/(loss)	2.74	(0.06)	(0.84)	3.27	(0.84)	13.21
10	Total comprehensive income for the period/year (7+9)	86.03	81.92	45.91	229.31	246.07	313.49
11	Total comprehensive income for the period/year attributable to						
	a) Shareholders of the company	85.62	82.15	45.91	229.13	246.07	313.49
	b) Non-controlling interest	0.41	(0.23)	-	0.18	-	-
12	Paid-up equity share capital	25.46	25.46	25.46	25.46	25.46	25.46
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
13	Other equity						2,025.21
14	Earning Per Share (EPS)- (Face value of Rs.1/-)						
	a) Basic -	3.26	3.23	1.84	8.87	9.70	11.80
	b) Diluted	3.23	3.21	1.84	8.83	9.70	11.80
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

SIGNED FOR IDENTIFICATION PURPOSES



Notes

1) The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 12 February 2025. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion. The financial results for the quarter and nine months ended 31 December 2023 and year ended 31 March 2024 were reviewed/audited by Kary & Co., Chartered Accountants ('predecessor auditors').

2) The above financial results are prepared in accordance with the Indian Accounting Standard prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3) The Company reportable activity falls under single operating segment i.e. Manufacturing (CRAMS) - Bulk Drugs & Intermediates & Services, hence segment reporting as per Ind AS 108 (Operating Segment) is not presented.

4) Pursuant to definitive agreements entered by the company with Sapala Organics Private Limited ("Sapala"), the Company has acquired 51% of the share capital on a fully diluted basis (i.e., 67.5% of the present equity share capital) of Sapala on 12 July 2024 for a consideration of ₹258.00 crore and gained control of Sapala Organics Private Limited ("Sapala") as a subsidiary. As at 12 July 2024, the fair value of assets and liabilities acquired had been determined by the Group and accounted for in accordance with IND AS 103 - "Business Combination" based on provisional purchase price allocation.

Consolidated financial results for the quarter ended 30 September 2024, 31 December 2024 and nine months ended 31 December 2024, include the impact of the above transaction with effect from 12 July 2024 and are not comparable with previous corresponding periods.

5) Pursuant to definitive agreements entered by the Company with NJ Bio Inc ("NJ Bio"), the Company has acquired 56% of the share capital of NJ Bio Inc on 20 December 2024 for a consideration of ₹547.96 crore and gained control of NJ Bio Inc ("NJ Bio") as a subsidiary. As at 20 December 2024, the fair value of assets and liabilities acquired have been determined by the Group and accounted for in accordance with IND AS 103 - "Business Combination".

As per the Share Purchase Agreement, NJ Bio has issued a put option to acquire the shares held by minority shareholders. The Put option obligation has been accounted for as a liability on the acquisition date at its fair value of ₹426.31 crore with a corresponding debit to other equity.

The fair value of assets and liabilities acquired have been provisionally determined by the Company and accounted for in accordance with IND AS 103 - "Business Combination". Consolidated financial results for the quarter and nine months ended 31 December 2024, include the impact of the above transaction with effect from 20 December 2024 and are not comparable with previous corresponding periods.

Total consideration has been allocated based on provisional purchase price allocation as under:

Particulars	Amount (₹ In crores)
Fair value of assets acquired including intangible assets	539.58
Fair value of liability assumed	(235.13)
Deferred tax liabilities on fair value of net assets acquired	(28.38)
Fair value of net assets acquired (A)	276.07
Non-controlled interest in the acquired entity, based on their proportionate interest in the recognised amounts of identifiable net assets of NJ Bio (B)	121.46
Total consideration paid (C)	547.96
Goodwill ((B+C)-A)	393.35

6) The Board of Directors had approved on 29 February 2024, the Scheme of Amalgamation of Cohance Life Sciences Limited (Transferor Company) into and with Suven Pharmaceuticals Limited ('The Company').

Based on the NCLT order dated 22 October 2024, meetings of the equity shareholders of both the Transferor Company and the Transferee Company were held on 28 November 2024 to consider and approve the Scheme. The Scheme has been approved by the Members of the Company with requisite majority.

The Scheme of Amalgamation remains subject to applicable approvals, including approvals from the Hon'ble NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities, as may be applicable.

7) The Board of directors of Suven Pharmaceuticals Limited ("Company" / "Transferee Company") has approved on 29 February 2024, the scheme of amalgamation of Casper Pharma Private Limited ("Transferor Company") (a wholly owned subsidiary of the Company) into and with the Company under the provisions of Sections 230 to 232 of the Companies Act, 2013 subject to receipt of applicable approval including approval from Hon'ble NCLT ("Scheme of Amalgamation").

The Hon'ble NCLT, Mumbai vide its Order dated 24 October 2024 has sanctioned the Scheme of Amalgamation. The Company has filed the certified copy of the Order with Registrar of Companies on 4 December 2024. As per the Scheme, the Appointed date which is also the effective date of the Scheme has been determined as 1 January 2025. Accordingly, the Scheme shall be accounted from the Appointed/ Effective date i.e. 1 January 2025 and in the manner prescribed under the scheme.

8) The figures of the previous year/periods have been regrouped/recast to render the classification comparable with that of current period.

9) The financial results for the quarter and nine months ended 31 December 2023 and for the year ended 31 March 2024 were presented in INR Lakhs. With effect from quarter ended 30 June 2024, the Company has presented the financial results in INR crores. Consequently, the results for the comparative periods have also been presented in INR Crores.

**SIGNED FOR
IDENTIFICATION
PURPOSES**



For and on behalf of the Board
Suven Pharmaceuticals Limited

Vivek Sharma
Executive Chairman
08559495

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Suven Pharmaceuticals Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Suven Pharmaceuticals Limited ('the Company') for the quarter ended 31 December 2024 and the year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above and the consideration of the review reports of the branch auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.



Walker ChandioK &Co LLP

5. We did not review the interim financial information of one branch (Suven Pharmaceuticals Limited – Branch Office, USA) included in the Statement, where such interim financial information reflects total revenues of ₹Nil, total net loss after tax of ₹(12.44) crores and ₹(20.36) crores, total comprehensive loss of ₹(12.44) crores and ₹(20.36) crores, for the quarter and year-to-date period ended on 31 December 2024, respectively, as considered in the Statement. Such interim financial information has been reviewed by the branch auditor, whose reports have been furnished to us by the management, and our conclusion, in so far as it relates to the amounts and disclosures included in respect of this branch, is based solely on the review report of branch auditor.

Further, the above branch is located outside India whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by branch auditor under Statement on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. The Company's management has converted the financial information of the branch from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management. Our conclusion, in so far as it relates to the balances and affairs of this branch is based on the review report of branch auditors and the conversion adjustments prepared by the management of the Company and reviewed by us.


Our conclusion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done by and the reports of the branch auditors.

6. The review of standalone unaudited quarterly and year-to-date financial results for the period ended 31 December 2023 and audit of standalone financial results for the year ended 31 March 2024 included in the Statement was carried out and reported by M/s. Karvy & Co., Chartered Accountants who has expressed unmodified conclusion vide their review report dated 5 February 2024 and unmodified opinion vide their audit report dated 30 May 2024, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker ChandioK & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013


Ashish Gupta
Partner

Membership No. 504662

UDIN: 25504662BMOODT1621



Place: New Delhi

Date: 12 February 2025

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Suven Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Suven Pharmaceuticals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associate (refer Annexure 1 for the list of subsidiaries and associate included in the Statement) for the quarter ended 31 December 2024 and the consolidated year to date results for the period 01 April 2024 to 31 December 2024 being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.



Walker Chandio & Co LLP


4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the branch auditors and other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We did not review the interim financial information of one subsidiary included in the Statement and one branch (Suven USA branch) included in the unaudited interim standalone financial statements of the entities included in the Group, whose financial information reflects total revenues of ₹Nil crores and ₹Nil crores, total net loss after tax of ₹(13.12) crores and ₹(21.29) crores, total comprehensive loss of ₹(13.12) crores and ₹(21.29) crores, for the quarter and year-to-date period ended on 31 December 2024, respectively, as considered in the respective unaudited interim standalone financial information of the entities included in the Group. These interim financial information have been reviewed by other auditors and branch auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of the subsidiary and a branch is based solely on the review reports of such other auditors and branch auditors and the procedures performed by us as stated in paragraph 3 above.

Further, the above subsidiary and a branch are located outside India, whose interim financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors and branch auditors under Statement on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. The Holding Company's management has converted the financial statements of such subsidiary/branch from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of the subsidiary/branch is based on the review report of other auditors and branch auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The review of unaudited consolidated quarterly and year-to-date financial results for the period ended 31 December 2023 and audit of standalone financial results for the year ended 31 March 2024 included in the Statement was carried out and reported by M/s. Karvy & Co., Chartered Accountants who have expressed unmodified conclusion vide their review report dated 5 February 2024 and unmodified opinion vide their audit report dated 30 May 2024, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandio & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013


Ashish Gupta
Partner
Membership No. 504662



UDIN: 25504662BMOODU6892

Place: New Delhi
Date: 12 February 2025

Walker ChandioK &Co LLP

Annexure 1

List of entities included in the Statement

Subsidiaries

1. Casper Pharma Private Limited, India
2. Sapala Organics Private Limited, India (with effect from 11 July 2024)
3. Suven Pharma Inc, USA
4. NJ Bio Inc, USA (with effect from 20 December 2024)
5. NJ Bio India Pharmaceuticals Private Limited, India (with effect from 20 December 2024)
6. NJ Biotherapeutics LLC, USA (with effect from 20 December 2024)

Associates

1. Aruka Bio Inc, USA (with effect from 20 December 2024)

Branch Office

1. Suven Pharmaceuticals Limited - Branch office, USA



B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.: Not Applicable

C. Format for disclosing outstanding default on loans and debt securities: Not Applicable

D. Format for disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter): Not Applicable

E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter): Not Applicable

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236